Table 1.
Baseline patient characteristics.
Table 2.
Clinician- and patient-reported outcomes.
Fig 1.
Effectiveness and patient-reported outcomes during 4 weeks of cyclosporine treatment.
(A) Median EASI scores at baseline (week 0), after 2 weeks and after 4 weeks. (B) Median NRS itch scores at baseline (week 0), after 2 weeks and after 4 weeks. (C) Median POEM scores at baseline (week 0), after 2 weeks and after 4 weeks. Error bars represent the interquartile range. ****p < 0.0001.
Fig 2.
Proteomic changes after 2 and 4 weeks of CsA treatment.
(A) Heatmap of differentially expressed proteins (DEPs) (fold change>1.5, p < 0.05, q < 0.05) after 2 weeks of CsA treatment, with markers grouped by unsupervised hierarchical clustering based on the 14 DEPs. Yellow color denotes higher and blue color denotes lower mean expression levels. (B) Volcano plot of DEPs after 2 weeks of treatment, the x-axis represents the value of log2-FC and the y-axis represents the mean value of –log10 (p-value). (C) Heatmap of DEPs (fold change>1.5, p < 0.05, q < 0.05) after 4 weeks of CsA treatment, with markers grouped by unsupervised hierarchical clustering based on the 21 DEPs. (D) Volcano plot of DEPs after 4 weeks of treatment, the x-axis represents the value of log2 fold change and the y-axis represents the –log10 (p-value).
Fig 3.
Correlations of disease severity, as measured by EASI score, with serum protein levels.
(A) Correlation of TNFRSF4/OX40 levels and EASI score. (B) Correlation of CCL17/TARC and EASI score. EASI, Eczema Area and Severity Index.
Fig 4.
Baseline predictive biomarkers for CsA treatment response.
(A) Heatmap of differentially expressed proteins (DEPs) (fold change <1.5, p < 0.05, q = 0.2) between>EASI 75 good responders (n = 21, red) and <EASI-75 responders (n = 17, green) at baseline, with markers grouped by unsupervised hierarchical clustering based on the 16 DEPs. Yellow color denotes higher and blue color denotes lower mean expression levels. (B) A volcano plot showing the differential level of proteins between>EASI 75 good responders (n = 21) and <EASI-75 responders (n = 17) at baseline. The x-axis represents the value of log2 fold change and the y-axis represents the –log-10 (p-value).
Fig 5.
ROC model predictive biomarkers for CsA treatment response.
ROC curves of a four-protein based model (black) and curves per individual protein based on odds ratio (OR) of the significant proteins predicting EASI-75 responders. Area under the ROC curve was 0.88 for the final model while individual proteins ranged from 0.6-0.7.